NetApp Expands Intelligent Data Infrastructure Capabilities to Power Strategic Cloud Workloads
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the introduction of new capabilities designed for strategic cloud workloads including GenAI and VMware. These enhancements to NetApp data and storage services reduce the resources and risks for customers to manage these strategic workloads across increasingly complex hybrid multicloud environments.
“Strategic workloads, including GenAI and virtualized environments, are driving business innovation and have increasingly complex and resource-intensive infrastructure requirements that are pushing IT teams to the limit,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage at NetApp. “NetApp is helping customers take back control of their data with intelligent data infrastructure that leverages unified data storage, integrated data services, and automated cloud operations. Even when they are up against specific and nuanced technology requirements for modern workloads, NetApp gives them the tools they need to optimize and simplify their data operations in their environments across the hybrid multicloud.”
To advance intelligent data infrastructure deployments that better support strategic workloads like GenAI and VMware environments, NetApp is announcing new capabilities, including:
- NetApp BlueXP Workload Factory – for AWS: This intelligent data infrastructure service uses defined industry best-practices to automate the planning, provisioning, and management of cloud resources and services for key workloads, including GenAI, VMware cloud environments, and enterprise databases. Customers can use BlueXP workload factory to optimize deployment time, cost, performance, and protection of resources for strategic workloads as well as their associated data. To simplify workload migrations to the cloud, BlueXP workload factory allows users to profile infrastructure requirements for target workloads and compare different resource options for cost and performance needs. Then, the service can provision the selected resources, move any existing workload data to these newly provisioned cloud deployments, and continually optimize the entire environment to ensure the required cost and performance targets. AWS users can read guidance on how to deploy this capability on the AWS Solutions Library.
- NetApp GenAI Toolkit – Microsoft Azure NetApp Files Version: Customers can now include private enterprise data stored in Azure NetApp Files in their retrieval-augmented generation (RAG) workflows in a secure, programmatic manner. The result is an enhanced ability to generate unique, high-quality, and ultra-relevant results from GenAI projects by combining their proprietary data with pre-trained, foundational models (FMs). The integration of the NetApp GenAI Toolkit with Azure NetApp Files represents a powerful synergy that empowers customers to harness advanced language generation capabilities.
- Amazon Bedrock with Amazon FSx for NetApp ONTAP Reference Architecture: Amazon Web Services, Inc. (AWS) and NetApp have released a joint reference architecture which provides guidance for customers on implementing RAG-enabled workflows that bring proprietary data stored on Amazon FSx for NetApp ONTAP into their GenAI data pipelines. Amazon FSx makes it easy and cost effective to launch, run, and scale feature-rich, high-performance file systems in the cloud. The reference architecture allows developers to use APIs for Amazon Bedrock to connect with Amazon FSx for ONTAP data stores, enabling the secure use of proprietary data with a choice of high-performing FMs that can be customized to unlock new insights and capabilities.
- Amazon FSx for NetApp ONTAP Enhancements: AWS announced the next-generation Amazon FSx for ONTAP cloud storage service with enhanced capabilities to boost scalability and flexibility to provide up to 6 GB per second of throughput for a single highly-available (HA) pair from 512 TiB of SSD storage. Next-gen file systems offer virtualized workloads more room to grow with a 300 percent increase in network burst throughput and a 150 percent boost in disk burst throughput. For large-scale, high-performance workloads like GenAI, second-generation Amazon FSx for ONTAP systems support dynamic scalability by adding HA pairs as needed, up to 24 nodes. This delivers up to 72 GB per second of throughput from 1 PiB of SSD storage, providing greater flexibility and performance for evolving business needs.
- NetApp BlueXP Disaster Recovery Support for VMFS: The BlueXP disaster recovery service, which provides guided workflows to design and execute automated disaster recovery plans for VMware workloads across both on-premises and cloud environments, has been expanded to support VMFS datastores for on-premises to on-premises disaster recovery.
These updates build on NetApp’s existing offerings that support storage and data operations for customers that need to implement and manage high-powered, strategic workloads such as GenAI and VMware environments. For example, NetApp recently announced that its unique BlueXP data classification capability, which automatically classifies and categorizes data for enhanced governance and secure ingest into GenAI and RAG data pipelines, has become a core control plane capability now available free of charge to all NetApp customers.
“When it comes to GenAI, the prime focus for organizations is to adapt their data strategies to ensure they can balance data security, cost efficiency and innovation as they leverage pre-built LLMs to surface relevant, useful insights from their proprietary, business-relevant data,” said Archana Venkatraman, Senior Research Director, Cloud Data Management at IDC. “NetApp’s intelligent data infrastructure capabilities can help customers overcome the data challenges and offer specific guidance to automate workflows that can securely feed private data directly into public cloud providers’ LLMs. In addition, NetApp’s BlueXP data classification capability has the potential to mitigate the risks in data operations for AI because it allows users to discover and categorize data so that the right data is fed into the right model without exposing confidential, personal or restricted information.”
“Organizations are now facing different economic realities with regards to virtualized environments, and we all need to move quickly to address recent industry shifts,” said Derek Elbert, Solutions Architect at WWT. “Optimizing the cost versus performance equation of VMware workloads has become a primary initiative for us, with the objective of continuing to provide scalability and performance while reducing unnecessary system and software resources. NetApp’s offerings, such as the BlueXP disaster recovery service and the optimization metrics from Cloud Insights, help us better ensure the right levels of resource allocation and protection schemes for virtual environments, allowing us to focus on putting our infrastructure to work without killing the FinOps metrics.”
Additional Resources
- When You Realize It’s More About Data Than About Storage
- Big News For All NetApp Customers: Classify Your Data with an Industry-Leading Solution at No Cost
- Power Your Generative AI on AWS
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710415938/en/
Contacts
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Kris Newton
NetApp
kris.newton@netapp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom